Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 source : Www.alnylam.com save search
18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at SFNP
Published: 2022-01-21 (Crawled : 13:00) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -10.41%
H: 0.0%
C: 0.0%
results phase 3
New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
phase 1 results phase 2 phase 3
New Results from ATLAS Phase 3 Program with Fitusiran Presented at ASH Annual Meeting 2021
Published: 2021-12-12 (Crawled : 20:20) - alnylam.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 2.8%
H: 0.0%
C: 0.0%
results phase 3
ILLUMINATE-B Phase 3 Results of OXLUMO® (lumasiran) Published in Genetics in Medicine
Published: 2021-12-09 (Crawled : 15:30) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.29%
H: 0.31%
C: -2.8%
oxlumo genetic results phase 3
Results from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at ASN Kidney Week 2021
Published: 2021-11-05 (Crawled : 18:00) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
results phase 3 kidney
Complete Results from Phase 1/2 Study of Lumasiran (OXLUMO®) Published in Clinical Journal of the American Society of Nephrology
Published: 2021-05-15 (Crawled : 04:20) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
| Email alert
Add to watchlist
phase 1 results phase 3 phase 2
HELIOS-A Phase 3 Results for Vutrisiran Presented at AAN
Published: 2021-04-19 (Crawled : 19:00) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -4.11%
H: 3.92%
C: 3.25%
results phase 3 presentation
ILLUMINATE-A Phase 3 Results for Lumasiran Published in The New England Journal of Medicine
Published: 2021-03-31 (Crawled : 22:00) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 1.4%
H: 1.39%
C: -0.95%
results phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.